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Adult-onset neurodegenerative disorders are disabling and often fatal diseases of the nervous systemwhose
underlying mechanisms of cell death remain unknown. Defects in mitochondrial respiration had previously
been proposed to contribute to the occurrence of many, if not all, of the most common neurodegenerative
disorders. However, the discovery of genes mutated in hereditary forms of these enigmatic diseases has
additionally suggested defects in mitochondrial dynamics. Such disturbances can lead to changes in mito-
chondrial trafficking, in interorganellar communication, and in mitochondrial quality control. These new
mechanisms by which mitochondria may also be linked to neurodegeneration will likely have far-reaching
implications for our understanding of the pathophysiology and treatment of adult-onset neurodegenerative
disorders.Adult-onset neurodegenerative diseases are a large group of
heterogeneous disorders characterized by the relatively selec-
tive death of neuronal subtypes. In most cases, they arise for
unknown reasons, and are relentlessly progressive. Age is the
most consistent and robust risk factor for neurodegenerative
diseases, and thus, the number of patients is expected to
increase dramatically in the years to come, especially in industri-
alized countries. For instance, the number of cases of Alz-
heimer’s disease (AD) and other dementias, including Lewy
body disease and frontotemporal dementia, was estimated by
the World Health Organization in 2005 at almost 25 million indi-
viduals worldwide, with 5 million new cases annually, and is
projected tomore than double by 2025. Existing approvedmedi-
cines provide only symptomatic relief, and their chronic use is
often associated with deleterious side effects; none appear to
modify the natural course of the diseases. Clearly, the develop-
ment of effective therapies is hindered by our limited knowledge
of the molecular mechanisms underlying these conditions.
Despite the phenotypic diversity of neurodegenerative disor-
ders, insights gained in the last decade into their pathophysi-
ology, especially through genetics, have begun to reveal some
underlying themes. These include disturbances in cellular quality
control mechanisms (e.g., endoplasmic reticulum [ER] stress,
defects in proteasomal and autophagic function, and accumula-
tion and/or aggregation of misfolded proteins), oxidative stress,
neuroinflammation, and impaired subcellular trafficking. Another
pathogenic theme that has come to prominence, and which is
the focus of this review, is the role of impaired mitochondrial
function, not only as it pertains to defects inmitochondrial energy
production, but also to mitochondrial dynamics (i.e., organellar
shape, size, distribution, movement, and anchorage), communi-
cation with other organelles, and turnover.
Of necessity, we have limited our discussion to a subset of
neurodegenerative disorders (Table 1), focusing on thosethat best illustrate our central points. We recognize that this
selection introduces a bias, yet the diseases we have chosen
encompass the vast majority of patients afflicted with neurode-
generative disease, and thus should provide a faithful picture
of the state of affairs regarding the role of mitochondria in neuro-
degeneration.
Can Genetics Shed Light onto the Mitochondrial Link
in Neurodegenerative Disorders?
Many of the prominent adult-onset neurodegenerative disor-
ders, such as AD, Parkinson’s disease (PD), and amyotrophic
lateral sclerosis (ALS), are primarily sporadic, i.e., they occur in
the absence of any genetic linkage. However, in rare instances
they can be inherited. The phenotypes of both the sporadic
and familial forms of these diseases are essentially indistinguish-
able, implying that they might share common underlying mech-
anisms. We believe that this similarity justifies the analysis of
rare genetic forms of a common sporadic disorder, as it could
well illuminate the pathogenesis of both. Moreover, the familial
counterparts of all of the common sporadic neurodegenerative
disorders are due to mutations not just in a single gene, but in
multiple distinct and often ostensibly dissimilar genes. This
apparent genetic heterogeneity associated with specific
syndromes should not come as a surprise, since thus far the
taxonomy of neurodegenerative disorders rests on clinical,
biochemical, and neuropathological criteria, lumping under the
same label diseases that merely look alike. Nonetheless, this
striking situation raises the possibility that however disparate
these genes may appear to be, the functions of the respective
gene products might intersect in common pathways. Further-
more, the observations that mutations in a specific gene can
give rise to more than one distinct clinical phenotype (Chen
et al., 2004; Elden et al., 2010; Moreira et al., 2004; Pulst et al.,
1996) suggest that while the disease classification scheme isNeuron 70, June 23, 2011 ª2011 Elsevier Inc. 1033
Table 1. Selected Neurodegenerative Disorders Discussed
Name
Frequency
per 100,000 Presentation
Typical Age of
Onset (Yr.)
Main Clinical
Manifestations
Main Neuropathological
Features
Alzheimer’s
disease
(AD)
1600 >90% sporadic,
<10% familial
>60 (often
younger
for familial
cases)
cognitive impairment primarily
featuring memory problems
(e.g. trouble in remembering
recent events, the names of
people and things); as the
disease progresses, language
(e.g. inability to recall vocabulary),
perceptual skills, attention,
constructive abilities, orientation,
problem solving, and functional
ability difficulties also arise, as well
as behavioral and neuropsychiatric
changes, including wandering,
irritability, and labile affects
gross cerebral cortex atrophy
(particularly in the temporal, parietal,
and parts of the frontal lobes,
and in the cingulate gyrus) due to
a loss of neurons and synapses;
these changes are associated with
amyloid plaques and neurofibrillary
tangles
Amyotrophic
lateral sclerosis
(ALS)
1 to 3 >90% sporadic,
<10% familial
55 (often
younger
for familial
cases)
muscle wasting and weakness,
and increased muscle tone
loss of cortical and spinal
motor neurons, degeneration of
corticospinal track, multiple forms
of pertinacious inclusions, gliosis
Charcot-Marie-
Tooth disease
(CMT)
40 familial;
autosomal dominant,
recessive, X-linked
5 to 25
(sometimes
>30)
progressive disorder of the
peripheral nerves giving rise
to weakness, muscle wasting,
and sensory loss, predominantly
in the feet and legs, but also in
the hands and arms in advanced
stages; often the first
manifestation is difficulty
in walking
degenerative changes are seen
in the peripheral nerves, where
a reduction of large myelinated
motor and sensory fibers is
observed; spared fibers show
damaged axons and myelin
sheaths, with the distal part of
the nerve often more affected than
the proximal part; in some forms
of CMT, the affected nerve
may be enlarged and show
‘‘onion-bulb’’ formation of
Schwann and fibroblast cells
Huntington’s
disease (HD)
3 to 7 familial;
autosomal dominant;
CAG trinucleotide
expansions in the
huntingtin gene
40 to 50
(of note, the
greater the
number of CAG
repeats, the
earlier
the onset)
often begins with personality
changes (e.g. irritability) and
mood disturbances (e.g.
depression) followed by abnormal
movements of a choreic nature,
primarily of the face and fingers;
as the disease progresses, chorea
spreads, athetoid and dystonic
monuments appear, and
intellectual functions decline,
giving rise to a dementia
gross atrophy of caudate nucleus
and putamen accompanied with
mild frontal and temporal atrophy;
the most salient neurodegenerative
changes involve a loss of medium-
size spiny neurons in the
striatopallidal and striatonigral
pathways associated with striatal
gliosis
Hereditary
spastic
paraparesis
(HSP)
4 to 6 familial;
autosomal dominant,
recessive, X-linked
<35 or 40
to 60
difficulty in walking and poor
balance are often the first signs;
progressive increased muscle
tone, brisk reflexes, muscle
weakness, bladder disturbances,
and paresthesia are part of the
core manifestations; depending
on the genetic form, ataxia,
dementia, abormal movements,
visual dysfunction, epilepsy,
or even extraneurological signs
may be observed
axonal degeneration primarily
in the corticospinal tracts and the
fasciculus gracilis, and to a lesser
extent in the spinocerebellar tract;
loss of anterior spinal horn is
observed in some cases; dorsal
root ganglia, posterior roots, and
peripheral nerves are normal
Optic atrophy
(OA)
2 to 10 familial;
autosomal dominant,
recessive, X-linked,
mitochondrially inherited
18 to 25 progressive bilateral visual loss;
central vision affected prior
to peripheral vision
degeneration of the retinal
ganglion cell bodies and
axonal pathways up to the
lateral geniculate nuclei
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Table 1. Continued
Name
Frequency
per 100,000 Presentation
Typical Age of
Onset (Yr.)
Main Clinical
Manifestations
Main Neuropathological
Features
Parkinson’s
disease (PD)
160 >90% sporadic,
<10% familial
60 (often
younger
for familial
cases)
tremor, slowness of movements,
stiffness, poor balance; as the
disease progresses, nonmotor
manifestations arise, including
dementia, constipation, sleep
disturbances, and orthostatic
hypotension
loss of pigmented neurons in ventral
midbrain (e.g. substantia nigra pars
compacta) and other pigmented
nuclei (e.g. locus ceruleus, dorsal
motor nucleus of the vagus);
intraneuronal Lewy body
inclusions; gliosis
Spinocerebellar
ataxias (SCA)
1 to 4 familial;
autosomal dominant,
recessive, X-linked;
30 different gene
mutations, but a CAG
trinucleotide expansion
(in different genes) is
found in several forms
<10 to >60 progressive incoordination of
gait, often associated with
poor coordination of hands,
speech, and eye movements;
dementia, movement disorders
such as parkinsonism, myoclonus,
seizures, retinal degeneration,
optic atrophy, and peripheral
neuropathy are observed in
some forms of SCA
degeneration of the spinal cord
and the cerebellum, as well as
many nuclei of the basal
ganglia and the brainstem
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degenerative disorders as reflecting different, and perhaps
more nuanced, expressions of shared, fundamental underlying
problems.
In the last several years, 188 separate genetic loci have been
associatedwith inherited forms of the eight adult-onset neurode-
generative syndromes that we have selected (AD, ALS, Charcot-
Marie-Tooth disease [CMT], hereditary spastic paraparesis
[HSP], Huntington’s disease [HD], optic atrophy [OA], PD, and
spinocerebellar ataxias [SCA] [Table 1]), and 106 genes have
been identified (Table 2; see also Online Mendelian Inheritance
in Man, http://www.ncbi.nlm.nih.gov/omim). In connection to
the topic of this review, it is worth noting that of the 106 identified
genes, at least 36 have some type of association to mitochon-
drial function, either directly (i.e., via proteins in knownmitochon-
drial biochemical pathways and structure; 24 genes) or indirectly
(i.e., via proteins that are not necessarily targeted to mitochon-
dria, but that affect them secondarily, such as those associated
with the communication between mitochondria and the ER; 12
genes) (Table 3). The fraction of mitochondrial-resident gene
products associated with neurodegenerative disorders (24/
106, or 23%) is well above the proportion expected by mere
chance alone (8%, i.e., 1600 genes encoding mitochondrial
proteins/20,000 total protein-coding genes), suggesting
a predilection for defects in these organelles to be associated
with late-onset neurodegenerative disorders. Based on the
above discussion, let us start our journey through mitochondria
and see where the path of human genetics leads us.
Since We All Think First about Bioenergetics,
Let’s Talk about It
Mitochondria are organelles present in all cells of the body
(erythrocytes excluded), ranging from a few hundred to many
thousands, depending on cell type. Maternally inherited, they
are the locus for many of the body’s ‘‘housekeeping’’ functions,
including the biosynthesis of amino acids and steroids and the
beta-oxidation of fatty acids; they also play a central role inapoptosis. However, the function that sets this organelle apart,
and which is responsible for the cliche´ that mitochondria are
the ‘‘powerhouses of the cell,’’ is the production of adenosine
triphosphate (ATP), via the combined efforts of the tricarboxylic
acid cycle and the respiratory chain/oxidative phosphorylation
system (OxPhos). The respiratory chain is a set of biochemically
linked multisubunit complexes (complexes I, II, III, and IV)
and two electron carriers (ubiquinone/coenzyme Q and cyto-
chrome c). It uses the energy stored in food to generate a proton
gradient across the mitochondrial inner membrane, while at the
same time transferring electrons to oxygen, producing water.
The energy of the proton gradient drives ATP synthesis
via ATP synthase (complex V); the ATP is then distributed
throughout the cell.
The central importance of mitochondria for cellular energy
production is underscored by the discovery in the last 20 years
of numerous syndromes resulting from OxPhos defects (Di-
Mauro and Schon, 2003). The mitochondrial respiratory chain
is the product of a joint effort between the mitochondrial and
nuclear genomes. Mitochondria harbor their own DNA (mtDNA)
which is a 16.6 kb double-stranded circular DNA that encodes
13 of the 92 polypeptides of the OxPhos system (DiMauro
and Schon, 2003), while the nuclear DNA (nDNA) specifies 79
OxPhos structural polypeptides and more than 100 other pro-
teins required for the proper incorporation of cofactors (e.g.,
iron-sulfur proteins, hemes, and copper) and for the assembly
of the five respiratory chain complexes into an integrated system
(Ferna´ndez-Vizarra et al., 2009).
Patients with OxPhos dysfunction who carry mutations in
either mtDNA or nDNA present with a host of clinical features,
many of which are neurological, such as seizures, myoclonus,
ataxia, progressive muscle weakness, stroke-like episodes,
and cognitive impairment (DiMauro and Schon, 2003). However,
these manifestations do not typically overlap with either the
clinical or the neuropathological hallmarks of any of our selected
adult-onset neurodegenerative disorders (Table 1). Furthermore,
to a remarkable degree, mutations in both mtDNA and nDNANeuron 70, June 23, 2011 ª2011 Elsevier Inc. 1035
Table 2. Genes Associated with Inherited Forms of AD, ALS,
CMT, HSP, HD, OA, PD, and SCA
Type Inh. Gene Chromosome
Alzheimer disease (AD)
AD1 AD APP 21q21.3
AD2 ? APOE 19q13.32
AD3 AD PSEN1 14q24.2
AD4 AD PSEN2 1q42.13
AD5 ? ? 12p11–q13
AD6 ? ? 10q24
AD7 ? ? 10p13
AD8 ? ? 20p
AD9 ? ? 19p13.2
AD10 ? ? 7q36
AD11 ? ? 9p21.3
AD12 ? ? 8p12–q22
AD13 ? ? 1q21
AD14 ? ? 1q25
AD15 ? ? 3q22–q24
AD16 XL ? Xq21.3
Amyotrophic lateral sclerosis (ALS)
ALS1 AD SOD1 21q22.11
ALS2 (J) AR ALS2 2q33.1
ALS3 AD ? 18q21
ALS4 (J) AD SETX 9q34.13
ALS5 AR ? 15q15–q21
ALS6 AR FUS 16p11.2
ALS7 AD ? 20p13
ALS8 AD VAPB 20q13.32
ALS9 AD ANG 14q11.2
ALS10 AD TARDBP 1p36.22
ALS11 AD FIG4 6q21
ALS12 AD/AR OPTN 10p13
ALS13 AD ATXN2 12q24.12
? AR SPG11 15q21.1
? AD VCP 9p13.3
Charcot-Marie-Tooth disease (CMT)
CMT1A AD PMP22 17p12
CMT1B AD MPZ 1q23.3
CMT1C AD LITAF 16p13.13
CMT1D AD EGR2 10q21.3
CMT1F AD NEFL 8p21.2
CMT2A1 AD KIF1B 1p36.22
CMT2A2 AD MFN2 1p36.22
CMT2B AD RAB7A 3q21.3
CMT2B1 AR LMNA 1q22
CMT2B2 AR MED25 19q13.33
CMT2C AD TRPV4 12q24.11
CMT2D AD GARS 7p14.3
CMT2E AD NEFL 8p21.2
Table 2. Continued
Type Inh. Gene Chromosome
CMT2F AD/AR HSPB1 7q11.23
CMT2G AD ? 12q12–q13.3
CMT2H AR ? 8q21.3
CMT2I AD MPZ 1q23.3
CMT2J AD MPZ 1q23.3
CMT2K AD GDAP1 8q21.11
CMT2L AD HSPB8 12q24.23
CMT2M AD DNM2 19p13.2
CMT2N AD AARS 16q22.1
CMT4A AR GDAP1 8q21.11
CMT4B1 AR MTMR2 11q21
CMT4B2 AR SBF2 11p15.4
CMT4C AR SH3TC2 5q32
CMT4D AR NDRG1 8q24.22
CMT4E AD/AR EGR2 10q21.3
CMT4F AR PRX 19q13.2
CMT4G AR ? 10q23.2
CMT4H AR FGD4 12p11.21
CMT4J AR FIG4 6q21
CMTDIA AD ? 10q24.1–q25.1
CMTDIB AD DNM2 19p13.2
CMTDIC AD YARS 1p35.1
CMTX1 XL GJB1 Xq13.1
Huntington disease (HD)
HD AD HTT 4p16.3
Hereditary spastic paraplegia (HSP)
SPG1 XL L1CAM Xq28
SPG2 XL PLP1 Xq22
SPG3A AD ATL1 14q22.1
SPG4 AD SPAST 2p22.3
SPG5A AR CYP7B1 8q12.3
SPG6 AD NIPA1 15q11.2
SPG7 AR SPG7 16q24.3
SPG8 AD KIAA0196 8q24.13
SPG9 AD ? 10q23.3–q24.1
SPG10 AD KIF5A 12q13.3
SPG11 AR SPG11 15q21.1
SPG12 AD ? 19q13.11–q13.13
SPG13 AD HSPD1 2q33.1
SPG14 AR ? 3q27–q28
SPG15 AR ZFYVE26 14q24.1
SPG16 XL ? Xq11.2
SPG17 AD BSCL2 11q12.3
SPG18 AR ? 8p12–p11.21
SPG19 AD ? 9q33–q34
SPG20 AR SPG20 13q13.3
SPG21 AR SPG21 15q22.31
SPG22 XL SLC16A2 Xq13.2
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Table 2. Continued
Type Inh. Gene Chromosome
SPG23 AR ? 1q24–q32
SPG24 AR ? 13q14.3
SPG25 AR ? 6q23.3–q24.1
SPG26 AR ? 12p11.1–q15
SPG27 AR ? 10q22.1–q24.1
SPG28 AR ? 14q21.3–q22.3
SPG29 AD ? 1p31.1–p21.1
SPG30 AR ? 2q37.3
SPG31 AD REEP1 2p11.2
SPG32 AR ? 14q12–q21
SPG33 AD ZFYVE27 10q24.2
SPG34 XL ? Xq24–q25
SPG35 AR ? 16q21–q23.1
SPG36 AD ? 12q23–q24
SPG37 AD ? 8p21.1–q13.3
SPG38 AD ? 4p16–p15
SPG39 AR PNPLA6 19p13.2
SPG40 AD ATL1 14q22.1
SPG41 AD ? 11p14.1–p11.2
SPG42 AD SLC33A1 3q25.31
SPG44 AR GJC2 1q42.13
SPG45 AR ? 10q24.3–q25.1
? AR AIMP1 4q24
Optic atrophy (OA)
OPA1 AD OPA1 3q29
OPA2 XL ? Xp11.4–p11.21
OPA3 AD OPA3 19q13.32
OPA4 AD ? 18q12.2–q12.3
OPA5 AD ? 22q12.1–q13.1
OPA6 AR ? 8q21.13–q22.1
OPA7 AR TMEM126A 11q14.1
LHON M ND genes mtDNA
Parkinson disease (PD)
PARK1/4 AD SNCA 4q22.1
PARK2 AR PARK2/Parkin 6q26
PARK3 AD ? 2p13
PARK5 AD UCHL1 4p13
PARK6 AR PINK1 1p36.12
PARK7 AR PARK7/DJ-1 1p36.23
PARK8 AD LRRK2 12q12
PARK9 AR ATP13A2 1p36.13
PARK10 ? ? 1p32
PARK11 AD GIGYF2 2q37.1
PARK12 ? ? Xq21–q25
PARK13 ? HTRA2 2p13.1
PARK14 ? PLA2G6 22q13.1
PARK15 AR FBXO7 22q12.3
PARK16 ? ? 1q32
Table 2. Continued
Type Inh. Gene Chromosome
? AR SPG11 15q21.1
? AR NDUFV2 18p11.22
Spinocerebellar ataxia (SCA)
SCA1 AD ATXN1 6p22.3
SCA2 AD ATXN2 12q24.12
SCA3 AD ATXN3 14q32.12
SCA4 AD PLEKHG4 16q22.1
SCA5 AD SPTBN2 11q13.2
SCA6 AD CACNA1A 19p13.2
SCA7 AD ATXN7 3p14.1
SCA8 AD ATXN8 13q21.33
SCA8 AD ATXN8OS 13q21.33
SCA9 AD ? ?
SCA10 AD ATXN10 22q13.31
SCA11 AD TTBK2 15q15.2
SCA12 AD PPP2R2B 5q32
SCA13 AD KCNC3 19q13.33
SCA14 AD PRKCG 19q13.42
SCA15 AD ITPR1 3p26.1
SCA16 AD CNTN4 3p26.2
SCA17 AD TBP 6q27
SCA18 AD ? 7q22–q23
SCA19 AD ? 1p21–q21
SCA20 AD ? 11p13–q11
SCA21 AD ? 7p21.3–p15.1
SCA22 AD ? 1p21–q23
SCA23 AD ? 20p13–p12.3
SCA24 AR ? 1p36
SCA25 AD ? 2p21–p13
SCA26 AD ? 19p13.3
SCA27 AD FGF14 13q33.1
SCA28 AR AFG3L2 18p11.21
SCA29 AD ? 3p26
SCA30 AD ? 4q34.3–q35.1
SCA31 AD BEAN-TK2 16q21
SCAN1 AR TDP1 14q32.1
SCAR1 AR SETX 9q34.13
SCAR2 AR ? 9q34–qter
SCAR3 AR ? 6p23–p21
SCAR4 AR ? 1p36
SCAR5 AR ? 15q25.3
SCAR6 AR ? 20q11–q13
SCAR7 AR ? 11p15
SCAR8 AR SYNE1 6q25.2
SCAR9 AR ADCK3 1q42.13
SCAX1 XL ? Xp11.21–q21.3
DRPLA AD ATN1 12p13.31
FRDA1 AR FXN 9q21.11
(Continue on next page)
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Table 2. Continued
Type Inh. Gene Chromosome
FRDA2 AR ? 9p23–p11
IOSCA AR C10orf2/Twinkle 10q24.31
MIRAS AR POLG 15q26.1
? AR ANO10 3p22.1
? AD SCN8A 12q13.3
Disease classification as listed in OMIM. Inh., Inheritance; AD, autosomal
dominant; AR, autosomal recessive; M, mitochondrial; XL, X-linked.
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typically do not strike in adulthood, but rather in infancy (e.g.,
Leigh syndrome, which is a fatal, necrotizing encephalopathy).
Yet, some patients with OxPhos dysfunction do succumb later,
in their twenties or thirties (e.g., via Kearns-Sayre syndrome,
which is a sporadically occurring, fatal, multisystem disorder
featuring paralysis of the extraocular muscles, retinal degenera-
tion, and heart block), but it is atypical for mitochondrial patients
to survive much longer, and it is exceptional for any individual to
experience an onset of an OxPhos disease beyond the age of 40.
However, the age at onset and the severity of the disorder corre-
late well with the degree of ATP deficit caused by the mutation.
Thus, ‘‘mild’’ mutations could theoretically give rise to a slowly
progressive, late-onset neurodegenerative disease, such as
AD or PD. Such mild mutations typically arise in one of two
ways: either because the mutation per se does not cause
a severe OxPhos impairment (e.g., mutations in complex I
subunits cause Leber’s hereditary optic neuropathy, or LHON
[Sadun et al., 2011], a maternally inherited form of blindness),
or because the proportion of mutated mtDNAs coexisting with
normal mtDNAs (i.e., heteroplasmy) within affected neurons is
relatively low, such that the deficit in ATP production is only
partial, as is typically the case in oligosymptomatic mothers of
affected children (DiMauro and Schon, 2003). Still, even if
mtDNA mutations have the potential to provoke neuronal death,
the fact remains that there are now more than 200 documented
mutations in the 37 mtDNA-encoded genes, and an equal
number in almost 100 nDNA-encoded OxPhos-related genes
(Smits et al., 2010), yet only a handful are associated with
adult-onset neurodegenerative disease. Among these, only
two well-documented mtDNA mutations are associated with
adult-onset neurodegeneration—one with Parkinsonism
(De Coo et al., 1999) and one with SCA (Silvestri et al., 2000)—
but, as far as we can tell, none with AD, ALS, CMT, HD, or
HSP. A number of mtDNA polymorphisms have also been asso-
ciated with some of these disorders, but their pathogenicity
remains to be established, and except for a few isolated reports
(Swerdlow et al., 1998), there is little evidence of maternal inher-
itance of neurodegenerative disease. Furthermore, mutations in
proteins required for mtDNA replication, such as those in mtDNA
polymerase g and in the helicase Twinkle, cause rare forms of
cerebellar degeneration (Hakonen et al., 2008). Also rare are
mutations in frataxin—which is required for the synthesis of
mitochondrial iron-sulfur proteins that are components of respi-
ratory complexes—causing Friedreich’s ataxia (Schmucker and
Puccio, 2010), and mutations in ADCK3/CABC1 that affect the1038 Neuron 70, June 23, 2011 ª2011 Elsevier Inc.synthesis of coenzyme Q of the respiratory chain, causing a
recessive form of SCA (Gerards et al., 2010).
The above discussion emphasizes that neurodegenerative
disorders, especially those of late onset, cannot be classified
neatly as canonical ‘‘primary mitochondrial cytopathies.’’ And
yet, it is possible that much is to be gained by viewing neuro-
degeneration through the prism of primary mitochondrial cyto-
pathies, because if we do not, we may fail to recognize a
bioenergetic component in the disease process. Take PD as
an example. A meta-analysis of genome-wide gene expression
microarray studies revealed the strongest association between
PD and genes encoding for OxPhos subunits and for enzymes
involved in glucose metabolism, all of which are regulated by
PGC-1a (Zheng et al., 2010), a transcriptional coactivator of
mitochondrial biogenesis (Puigserver et al., 1998). Relevant to
this observation is the identification of Parkin-interacting
substrate (PARIS), a partner of the PD-related protein Parkin
(see below) that represses PGC-1a expression (Shin et al.,
2011). These authors propose that inactivation of Parkin, either
by mutation or by environmental stress, leads to the accumula-
tion of PARIS and the ensuing inhibition of PGC-1a transcription,
which in turn may reduce mitochondrial biogenesis and cause
OxPhos deficiency. Thus, if PD is any guide, bioenergetic
defects could indeed play a role in common neurodegenerative
disorders, not somuch as the initiating factor of the neurodegen-
erative cascade but more as a pathogenically meaningful conse-
quence of some other perturbation (e.g., loss of Parkin activity).
So What Other Mitochondrial Problems Can Cause
Neurodegeneration?
The textbook image of mitochondria as bean-shaped organelles
that populate the cytoplasm in apparently random fashion belies
a far more dramatic reality (Braschi and McBride, 2010). Mito-
chondria are constantly on the go. They fuse and divide, branch
and fragment, swell and extend, exist in clusters and as indi-
vidual entities. Importantly, they travel throughout the cell, from
the cell body outwards (anterograde movement) and ‘‘home-
ward-bound’’ in the opposite direction (retrograde movement).
When not moving, they periodically anchor themselves on—
and then disengage from—other organelles, such as the ER,
endocytic vesicles, and the plasma membrane. In short, mito-
chondria are dynamic organelles that move from the cell body
to regions of the cell to deliver ATP and other metabolites where
they are most required, and then return. This is seen most strik-
ingly in highly elongated cells such as neurons: mitochondria are
enriched at presynaptic terminals at the ends of axons and at
postsynaptic terminals at the ends of dendrites, where bioener-
getic demand is particularly high. In addition, while this constant
motion helps the cell redirect and recycle mitochondria in an
efficient manner, ‘‘worn-out’’ mitochondria are ultimately
disposed of (and their component parts recycled) via autophagy
(‘‘mitophagy’’) or via extrusion of ‘‘mitochondria-derived vesi-
cles’’ (Braschi et al., 2010). The inability of mitochondria to
execute these functions would be expected to disrupt cellular
physiology and viability, and the degree of impairment likely
corresponds to that cell’s requirements for having well-func-
tioning mitochondria positioned in the right place at the right
time. For these reasons, there is growing enthusiasm for the
Neuron
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pivotal role in the pathogenesis of neurodegenerative disorders.
We will focus here on three ways that altered ‘‘mitodynamics’’
could contribute to adult-onset neurodegeneration (Chen and
Chan, 2009): aberrant mitochondrial trafficking, altered interor-
ganellar communication, and impaired mitochondrial quality
control (Figure 1).
Neurodegenerative Disorders and Mitochondrial
Trafficking
Organelles such as lysosomes, peroxisomes, and mitochondria
are not positioned statically within cells. Rather, they are trans-
ported on cytoskeletal elements, that is, microtubules and actin
cables, often in association with intermediate filaments (Jung
et al., 2004). Short-range movement on actin cables requires
myosin motors, whereas long-range movement on microtubules
requires two other types of motors: dynein/dynactin for retro-
grade transport and kinesins for anterograde transport (Hollen-
beck, 1996). Dynein-mediated retrograde movement appears
to be promiscuous, with no specific adaptor for mitochondria.
Kinesins, on the other hand, comprise a large superfamily,
among which is a subset that has been reported to associate
specifically with mitochondria (Zinsmaier et al., 2009).
Given the critical role of mitochondria in maintaining cell
viability, it stands to reason that defects in mitochondrial traf-
ficking could underlie neurodegenerative processes. Is there
evidence to support this view? We have approached this ques-
tion in two ways. First, we asked if there were evidence for per-
turbed mitochondrial trafficking in any of our selected set of
neurodegenerative diseases. Conversely, we examined situa-
tions where mitochondrial trafficking is known to be perturbed,
and asked whether the ensuing phenotypes were reminiscent
of any of our selected diseases.
Direct evidence that mitochondrial trafficking is altered in
human neurodegenerative disease patients is actually quite
limited. This paucity of data is not surprising, given both the
logistical hurdles in obtaining human samples and the difficulty
in analyzing mitochondrial transport in autoptic material. Never-
theless, of the disorders on our list, such evidence has been
reported in autoptic samples from patients with sporadic AD:
defects in axonal trafficking of molecular motor proteins and
organelles, including mitochondria, were inferred from the
observation of axonal swellings containing vesicles, vacuoles,
multilamellar bodies, and especially mitochondria, in the nucleus
basalis of Meynert; the formation of these vesicles was appar-
ently mediated by the expression of kinesin-1, a microtubule
motor (Stokin et al., 2005).
On the other hand, ample data for trafficking defects exist in
experimental models—mainly genetically engineered mice—of
a number of adult-onset neurodegenerative disorders. Both
anterograde (De Vos et al., 2007) and retrograde (Shi et al.,
2010) mitochondrial transport were reduced in motor neurons
from ALS mice expressing mutant superoxide dismutase-1
(SOD1). Even more remarkable, misfolded wild-type SOD1 im-
munopurified from a subset of patients with sporadic ALS and
perfused into isolated squid axoplasm inhibited fast axonal
transport (Bosco et al., 2010). This latter observation is particu-
larly noteworthy, as it reveals a remarkable potential connection
between the sporadic and familial forms of the disease.Altered mitochondrial trafficking and integrity have also been
observed upon overexpression of at least two other proteins
whose mutations cause familial forms of ALS. First, increased
expression of the wild-type guanine-nucleotide exchange factor
alsin in monkey COS7 cells was associated with disorganization
of the microtubule network and with organellar abnormalities,
including perinuclear clustering of mitochondria (Millecamps
et al., 2005). Second, transgenic mice expressing human TAR
DNA binding protein 43 (TDP-43) showed mitochondrial maldis-
tribution, with an excess ofmitochondria in the cell body ofmotor
neurons and a paucity of mitochondria in distal motor axon
terminals (Shan et al., 2010).
Thus far, our discussion of experimental models has revolved
mainly around pathologies of the motor neurons, in which mito-
chondria must travel exceedingly long distances. But what about
trafficking in disorders in which neuronswithmuch shorter axons
are the primary target of the disease? In fact, AD, a disorder
primarily of ‘‘short’’ neurons in the cortex and hippocampus,
displays features of aberrant axonal trafficking of cargo (Stokin
et al., 2005), and especially of altered mitochondrial trafficking
(Wang et al., 2009a) and dynamics (Wang et al., 2008, 2009b).
Moreover, published data suggest that HD, an adult-onset
fatal chorea involving relatively short striatopallidal neurons,
may also be a disorder of mitochondrial trafficking. HD is caused
by mutations—specifically expansions of a polyglutamine
stretch—in huntingtin (HTT), a protein of unknown function. In
transfected primary rat cortical neurons, mutant, but not wild-
type, HTT blocked mitochondrial movement (Chang et al.,
2006). Expression of mutant HTT in transgenic mice impaired
trafficking of vesicles and mitochondria, and mutant HTT prefer-
entially redistributed kinesin- and dynein-related proteins in
extracts from human HD brain (Trushina et al., 2004). These
effects on mitochondria and on trafficking were likely due specif-
ically to the polyglutamine expansion located within the
N-terminal region of HTT, as truncated fragments containing
the N-terminal region associated preferentially with mitochon-
dria in HTT knockin mice, and these mutant HTT fragments
affected mitochondrial trafficking in both the anterograde and
retrograde directions (Orr et al., 2008).
Other aspects of HTT function also point to mitochondrial
trafficking (Sack, 2010). The HTT binding partner huntingtin-
associated protein (HAP1) associates with membranous organ-
elles, including mitochondria (Gutekunst et al., 1998), and
interacts with both kinesin and dynein/dynactin to regulate the
transport of cargo on microtubules (Bossy-Wetzel et al., 2008).
Interestingly, Milton, one of two mitochondrial microtubule
adaptor proteins (the other is Miro; see below), is a HAP1
homolog, and it too binds HTT and dynactin (Stowers et al.,
2002). Taken together, these data support the possibility that
altered mitochondrial trafficking contributes to neurodegenera-
tion in HD.
More speculative, but still worth mentioning, is the potential
link between proteins known to cause familial PD and defects
in microtubule-mediated trafficking. The mitochondrial kinase
PTEN-induced putative kinase-1 (PINK1) may play a role in mito-
chondrial transport, as it was shown to form a multiprotein
complex with Milton and Miro (Weihofen et al., 2009), but the
effects of PD-linked mutations on this relationship are currentlyNeuron 70, June 23, 2011 ª2011 Elsevier Inc. 1039
Table 3. Genes Associated with Mitochondrial Function
Gene Subtype Protein Function/Comment aMito?
Proteins associated with neurotransmission (12)
ANO10 None anoctamin 10; Ca2+-activated Cl- channel chloride transport N
CACNA1A SCA6 Ca2+ channel, a-1A subunit calcium transport N
EGR2 CMT1D/4E early growth response 2 protein regulates myelin transcription N
GJB1 CMTX1 Gap junction protein b1 (connexin-32) role in myelination N
GJC2 SPG44 Gap junction protein g2 (GJA12) (connexin-47) role in myelination N
ITPR1 SCA15 IP3 receptor 1 calcium transport (enriched in MAM) N
KCNC3 SCA13 K+ channel potassium transport N
MPZ CMT1B/2I/2J myelin protein P0 myelin protein N
NDRG1 CMT4D N-myc downstream regulated 1 myelin maintenance protein, putative N
PMP22 CMT1A peripheral myelin protein 22 myelin protein N
PRX CMT4F periaxin myelin protein N
SCN8A None Na+ channel, type VIII, a subunit sodium transport N
Proteins associated with the cytoskeleton (25)
ATL1 SPG3A /40 atlastin 1 GTPase (also called SPG3) ER-modeling dynamin; interacts with spastin and
REEP1
N
ATN1 DRPLA atrophin-1 may interact with spartin via AIP4 N
DNM2 CMT2M/DIB dynamin-2 microtubule-associated force-producing protein N
FGD4 CMT4H frabin; FYVE/RhoGEF/PH domain containing 4 binds, regulates actin N
HSPB1 CMT2F heat shock protein 27 (HSP27) actin organization; binds microtubules N
HSPB8 CMT2L heat shock protein 22 (HSP22) chaperone; associated with autophagy N
KIF1B CMT2A1 kinesin 1B (CMT mutation in nonmito
KIF1Bb isoform)
KIF1Ba isoform transports mitochondria,
myelin mRNAs
Y
KIF5A SPG10 kinesin 5A microtubule motor protein; binds Milton Y
L1CAM SPG1 L1 cell adhesion molecule axonal glycoprotein N
MTMR2 CMT4B1 myotubularin-related protein 2 phosphoinositol-related phosphatase; interacts
with SBF2
N
NEFL CMT1F/2E neurofilament, light chain (NFL) intracellular transport to axons and dendrites Y
NIPA1 SPG6 nonimprinted in Prader-Willi/Angelman syndromes Mg2+ transporter; interacts w ATL1 N
OPTN ALS12 optineurin function unclear; binds ubiquitin; also causes glaucoma Y
PLEKHG4 SCA4 puratrophin-1 (Purkinje cell atrophy associated) actin dynamics; has a spectrin repeat domain N
REEP1 SPG31 receptor expression-enhancing protein 1 binds spastin and atlastin; associates with microtubules Y
SBF2 CMT4B2 myotubularin-related protein 13 (MTMR13) pseudophosphatase; interacts with MTMR2 N
SH3TC2 CMT4C SH3 domain and tetratricopeptide repeats 2 endosomal recycling with Rab11 N
SPAST SPG4 spastin severs microtubules; axonal branching Y
SPG20 SPG20 spartin binds microtubules; protein folding and turnover? Y
SPG21 SPG21 maspardin (ACP33 acidic cluster protein) axonal branching N
SPTBN2 SCA5 spectrin, b-III cytoskeletal protein N
SYNE1 SCAR8 synaptic nuclear envelope protein (nesprin-1) links organelles to the actin cytoskeleton;
has spectrin repeats
N
TTBK2 SCA11 Tau tubulin kinase 2 phosphorylates tau and tubulin N
VAPB ALS8 VAMP-associated protein B associates with microtubules; membrane transport N
ZFYVE27 SPG33 Zinc finger FYVE domain containing 27
(protrudin)
interacts w spastin; may not be pathogenic
(Martignoni et al., 2008)
N
Mitochondria-localized proteins (24)
ADCK3 SCAR9 ubiquinone synthesis regulatory kinase (CABC1) CoQ synthesis Y
AFG3L2 SCA28 paraplegin-like AAA protease mitochondrial protein degradation Y
ATXN3 SCA3 ataxin-3 deubiquitinase DNA repair; binds mitochondrial E3 ubiquitin
ligase MARCH5
Y
C10orf2 IOSCA Twinkle DNA/RNA helicase (PEO1) mtDNA replication Y
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Table 3. Continued
Gene Subtype Protein Function/Comment aMito?
FXN FRDA1 frataxin mitochondrial iron metabolism Y
GDAP1 CMT2K/4A ganglioside-induced differentiation-associated
protein 1
interacts with mitofusins Y
HSPD1 SPG13 heat shock protein 60 (HSP60) mitochondrial chaperone Y
HTRA2 PARK13 HtrA serine peptidase 2 (OMI) apoptosis Y
HTT HD huntingtin mutant HTT is mitochondrial; interacts
with microtubules
Y
MFN2 CMT2A2 mitofusin 2 mitochondrial fusion; MAM integrity Y
mtDNA LHON complex I subunits (mtDNA-encoded) respiratory chain function Y
NDUFV2 PD complex I subunit (nDNA-encoded) respiratory chain function Y
OPA1 OPA1 dynamin-related GTPase mitochondrial fusion Y
OPA3 OPA3 dynamin-related GTPase mitochondrial fusion? Y
PARK7 PARK7 DJ-1 atypical peroxidase; mitochondrial protein
quality control?
Y
PARKIN PARK2 Parkin mitophagy Y
PINK1 PARK6 PTEN-induced putative kinase 1 mitophagy Y
POLG MIRAS mitochondrial DNA polymerase g mtDNA replication Y
SNCA PARK1/4 a-synuclein function unclear Y
SOD1 ALS1 superoxide dismutase, Cu,Zn-containing redox regulation Y
SPG7 SPG7 paraplegin AAA protease mitochondrial protein quality control Y
TDP1 SCAN1 tyrosyl-DNA phosphodiesterase 1 topoisomerase I; DNA repair Y
TMEM126A OPA7 transmembrane protein 126A function unknown Y
VCP ALS valosin-containing protein/p97 retrotranslocation of proteins for proteasome
(cyto/ mito)
Y
Potential relationship with mitochondria and/or mitochondria-associated ER membranes (MAM) (17)
ALS2 ALS2 alsin guanine-nucleotide exchange factor for RAB5 N
APP AD1 amyloid precursor protein presenilin substrate (present in MAM) N
ATXN1 SCA1 ataxin-1 RNA metabolism N
ATXN10 SCA10 ataxin-10 binds GNB2 (mitochondrial), which binds MFN1
(mitochondrial)
N
BEAN-TK2 SCA31 BEAN-thymidine kinase 2 overlap region TK2 is mitochondrial; BEAN is not N
EGR2 CMT1D early growth response 2 protein transcription factor N
GARS CMT2D glycyl-tRNA synthetase protein synthesis (mitochondrial/cytosolic isoforms) Y
GIGYF2 PARK11 GRB10 interacting GYF protein 2 enhances activation of ERK1/2, which is mitochondrial Y
KIAA0196 SPG8 strumpellin; AAA protease binds VCP; degrades MOM proteins Y
LMNA CMT2B1 lamin A/C nuclear membrane N
LRRK2 PARK8 leucine-rich repeat Ser/Thr-protein kinase 2 function not clear N
PLA2G6 PARK14 phospholipase A2, group VI (iPLA2b) ER-mitochondrial crosstalk via ceramide
(probably in MAM)
Y
PPP2R2B SCA12 PP2A regulatory subunit 2Bb signaling (probably in MAM) Y
PSEN1 AD3 presenilin-1 aspartyl protease; in MAM N
PSEN2 AD4 presenilin-2 aspartyl protease; in MAM N
TARDBP ALS10 TAR DNA binding protein 43 (TDP43) DNA/RNA-binding protein,
regulates transcription/splicing
N
TBP SCA17 TATA box-binding protein transcription factor N
No obvious relationship to mitochondria (26)
AARS CMT2N alanyl-tRNA synthetase protein synthesis (cytoplasmic) N
ANG ALS9 angiogenin; RNAse A (RNASE4) tRNA-specific RNAse; binds actin on endothelial cells N
ATP13A2 PARK9 ATPase, P-type cation transporter N
(Continue on next page)
Neuron 70, June 23, 2011 ª2011 Elsevier Inc. 1041
Neuron
Review
Table 3. Continued
Gene Subtype Protein Function/Comment aMito?
ATXN2 ALS13/SCA2 ataxin-2 function unknown N
ATXN7 SCA7 ataxin-7 transcriptional regulation N
ATXN8 SCA8 ataxin-8 affects RNA-binding protein MBNL1 N
ATXN8OS SCA8 ataxin-8 opposite strand function unknown N
BSCL2 SPG17 seipin lipid droplet morphology; in ER N
CYP7B1 SPG5A 25-hydroxycholesterol 7-a-hydroxylase cholesterol catabolism in ER, 1st step N
FBXO7 PARK15 F-box only protein 7 ubiquitination N
FGF14 SCA27 fibroblast growth factor 14 signaling N
FIG4 ALS11/CMT4J polyphosphoinositide phosphatase (SAC3) synthesis of phosphatidylinositol-3,5-bisphosphate N
FUS ALS6 fused in sarcoma/translocated in liposarcoma
(FUS/TLS)
hnRNP protein N
LITAF CMT1C lipopolysaccharide-induced TNF-a factor stimulates monocytes/macrophages N
MED25 CMT2B2 mediator complex subunit 25 transcriptional coactivator N
PNPLA6 SPG39 neuropathy target esterase deacetylates intracellular phosphatidylcholine (in ER) N
PRKCG SCA14 protein kinase c, g type signaling; activated by Ca2+ and DAG N
RAB7A CMT2B Ras-related GTPase RAB7A endosomal; vesicle transport; phagosome maturation N
SETX ALS4, SCAR1 senataxin putative DNA/RNA helicase N
SLC16A2 SPG22 monocarboxylate transporter 8 (MCT8) thyroid hormone transporter N
SLC33A1 SPG42 acetyl-CoA transporter (AT-1; ACATN1) ER-Golgi sialylation N
SPG11 SPG11, PD spatacsin function unknown N
TRPV4 CMT2C transient receptor potential cation channel osmoregulation N
UCHL1 PARK5 ubiquitin C-terminal hydrolase protein degradation N
YARS CMTDIC tyrosyl-tRNA synthetase protein synthesis (cytoplasmic) N
ZFYVE26 SPG15 Zinc finger FYVE domain containing 26 spastizin (FYVE-CENT); centrosomal protein N
a Indicates whether the listed protein is known to be targeted directly to, or interacts indirectly with, mitochondria (Y, yes; N, no).
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differentiated SH-SY5Y neuroblastoma cells (which mimics the
multiplications of the normal gene found in some PD patients),
aggregates of the protein disrupted the microtubule network
and microtubule-dependent trafficking of cargoes (Lee et al.,
2006). On the other hand, both the PD-linked protein leucine-
rich repeat kinase-2 (LRRK2) and Parkin were found to alter
the balance between polymerized and depolymerized tubulin
(Gillardon, 2009; Yang et al., 2005), with downstream effects
on trafficking of cargo that still remain to be demonstrated.
Tomakematter evenmore complicated, just because a neuro-
degenerative disease gene is associated with the trafficking
machinery for intracellular cargo does not necessarily mean
that trafficking is the main problem. For example, in transfection
experiments, the HSP-related protein spartin was localized to
microtubules and mitochondria via determinants located in the
N- and C-terminal regions of the protein, respectively (Lu et al.,
2006). However, proteomic analysis implied that spartin plays
a different role, in protein folding and turnover, both in mitochon-
dria and ER (Milewska et al., 2009), andmay also be in involved in
lipid droplet formation (Hooper et al., 2010). A similar dilemma
surrounds another HSP-related protein, receptor expression-
enhancing protein 1 (REEP1). One group localized REEP1 to
mitochondria (Zu¨chner et al., 2006), while another group found
that REEP1 interacted with atlastin-1, another HSP-related
protein, within tubular ER membranes, thereby coordinating1042 Neuron 70, June 23, 2011 ª2011 Elsevier Inc.ER shaping with microtubule dynamics (Bian et al., 2011; Park
et al., 2010). However, despite the potential connection of both
spartin and REEP1 to microtubules and mitochondria, there is
no evidence that either one plays any role in mitodynamics,
even though mutations in both cause neurodegeneration.
These examples illustrate the challenge in relating pathology
to specific problems in mitochondrial dynamics. Perhaps
a more fruitful approach might be to start from situations where
mitochondrial trafficking is known to be perturbed, and then see
whether they produce phenotypes mimicking aspects of neuro-
degenerative disease. From the outset, it should be noted that
there are hardly any mutations in the structural components of
actin, dynein, or kinesin known to cause neurodegenerative
disease. In our survey, we found only three: mutations in kinesin
heavy chain isoform 1Bb cause CMT (Zhao et al., 2001), and in
isoform 5A, cause HSP (Ebbing et al., 2008), while mutations in
the p150Glued subunit of the dynein-associated protein dynactin
increase the risk of developing ALS (Mu¨nch et al., 2004). This
state of affairs probably reflects the essentiality of these motor
molecules to life. Nonetheless, a number of disorders are caused
by mutations in proteins that are associated with actin, dynein,
and kinesin in a secondary manner, among which five appear
to affect mitochondrial behavior.
Actin cables, like microtubules, have a polarity, with myosin
motors typically moving toward the ‘‘barbed’’ (+) end of actin fila-
ments and away from the ‘‘pointed’’ () end (Wells et al., 1999).
Figure 1. Mitochondrial Interactions in Neurodegenerative Diseases
Proteins associated with mutations causing neurodegenerative disorders are in colored ovals (colored according to the key), and are associated with four broad
mitochondrial functions (black rectangles). White ovals indicate selected relevant mitochondrial proteins not currently associated with neurodegenerative
disease. In general, only pathogenic proteins discussed in the text are shown; note that some proteins not discussed here are also associated with mitochondria,
either directly or indirectly (Table 3); HTRA2/OMI andHSPD1, associatedwith PD andHSP, respectively, are included in the figure for completeness, but were not
discussed in the text. Proteins that ‘‘touch’’ each other indicate a physical or genetic interaction. For simplicity, the figure does not show all interactions, or shows
some interactions that occur only in some tissues or at specific times, or both; conversely, some interactions are speculative, based on extrapolations from
the literature. See text for details. IMS, intermembrane space; MAM, mitochondria-associated ER membranes; MIM, mitochondrial inner membrane; MOM,
mitochondrial outer membrane; m, mutant; D-mtDNAs, large-scale partial deletions of mtDNA.
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site direction (Wells et al., 1999). It appears to play a role in asym-
metric partitioning of organelles and cytoskeletal components
during cell division, at least in worms, as deletion of myosin VI
in C. elegans resulted in a failure to deliver mitochondria tobudding spermatids (Kelleher et al., 2000). This ‘‘unconven-
tional’’ myosin has an indirect connection to at least two neuro-
degenerative diseases, ALS and HD, via one of its binding
partners, the cargo adaptor protein optineurin (Sahlender et al.,
2005).Mutations in optineurin, which have already been reportedNeuron 70, June 23, 2011 ª2011 Elsevier Inc. 1043
Neuron
Reviewto cause primary open-angle glaucoma (Fuse, 2010), cause ALS
(Maruyama et al., 2010). Optineurin also binds HTT, and plays
a role in cellular signaling, membrane trafficking, and cellular
morphogenesis (Anborgh et al., 2005; Hattula and Pera¨nen,
2000), providing further support that altered mitochondrial traf-
ficking plays a role in HD.
With respect to microtubule function, mutations in spastin,
a microtubule-severing protease causing HSP, resulted in
abnormal perinuclear clustering of mitochondria and peroxi-
somes in transfected HEK293 cells (McDermott et al., 2003)
and in axonal transport defects and mitochondrial clustering
on microtubules in spastin-mutated mice (Kasher et al., 2009).
Regarding intermediate filaments, mutations in neurofilament
light chain (NFL) cause CMT (Brownlees et al., 2002; Pe´rez-
Olle´ et al., 2005). Expression of mutant NFL in explanted
embryonic mouse motor neurons disrupted the neurofilament
network, but notably, rounding of mitochondria and reduction
in axonal diameter occurred prior to this event, implying that
mitochondrial dysfunction contributes to the pathogenesis of
the disease (Tradewell et al., 2009). Moreover, expression of
heat shock protein B1 in neurons expressing some CMT mutant
forms of NFL abrogated themitochondrial and trafficking pheno-
types. This result is not only consistent with the role of this
chaperone in neurofilament assembly, but also helps explain
whymutations in this heat shock protein also cause CMT (Trade-
well et al., 2009).
The strategy of examining defects in mitochondria-related
proteins has yielded a more compelling connection with adult-
onset neurodegenerative disorders, but this relationship is not
particularly obvious when viewing in toto all eight of the neurode-
generative disorders that we have selected. In fact, as can be
seen from the above discussion, mitochondrial connections
are prevalent in only two specific disorders, HSP and CMT,
both of which are axonopathies often associated with myelin
pathology (Table 1).
Neurodegenerative Disorders and Mitochondrial-ER
Communication
Mitochondria do not exist, or operate, in isolation, but associate
with many other subcellular organelles. Aside from connections
to cytoskeletal elements, mitochondria interact with, for ex-
ample, peroxisomes, lysosomes, Golgi, and ER. Among these,
the most intriguing is the connection between mitochondria
and ER. These two organelles are linked, both biochemically
and physically (Csorda´s et al., 2006), via mitochondria-associ-
ated ER membranes (ER-MAM, or MAM) (Rusin˜ol et al., 1994).
Located mainly in the perinuclear region of cells (Area-Gomez
et al., 2009; Schon and Area-Gomez, 2010), MAM has been re-
ported to be enriched in more than 75 proteins, including those
involved in calcium homeostasis (e.g., inositol-1,4,5-triphos-
phate [IP3] receptors [IP3Rs] and ryanodine receptors), in lipid
metabolism (e.g., phosphatidylethenolamine N-methyltransfer-
ase), in intermediate metabolism (e.g., glucose-6-phosphatase),
in cholesterol metabolism (e.g., acyl-coenzyme A:cholesterol
acyltransferase 1 [ACAT1]), in the transfer of lipids between the
ER and mitochondria (e.g., fatty acid transfer proteins 1 and 4),
and in ER stress (e.g., glucose-regulated proteins 75 and 78)
(Hayashi et al., 2009b). Contacts between the two organelles
are maintained by MAM-associated proteins, such as phospho-1044 Neuron 70, June 23, 2011 ª2011 Elsevier Inc.furin acidic cluster sorting protein-2 (Simmen et al., 2005) and
mitofusin-2 (MFN2), which is also required for mitochondrial
fusion (de Brito and Scorrano, 2008). Interestingly, fission-1
(FIS1), a protein required for mitochondrial fission, has recently
also been localized to the MAM (Iwasawa et al., 2011).
The relationship between MAM and calcium trafficking (Csor-
da´s et al., 2010) is worthy of some elaboration. As alluded to
above, two cargo adaptor proteins discovered initially in
Drosophila—Miro and Milton—are implicated in the specific
linkage of mitochondria to kinesin-1 in neurons. Miro is anchored
to the mitochondrial outer membrane (Guo et al., 2005), and
binds to themitochondrial-specific adaptor proteinMilton, which
is linked to the kinesin-1 heavy chain (Brickley et al., 2005; Glater
et al., 2006; Koutsopoulos et al., 2010). Miro is a calcium-binding
protein (Fransson et al., 2003), and thus has the potential for
being a regulator of mitochondrial motility in neurons, in essence
operating as a sensor of local [Ca2+] and ATP. It has been
proposed that in the Ca2+-unbound state, Miro binds Milton
and mitochondria are attached to microtubules, whereas in the
Ca2+-bound state, Miro cannot bind Milton and mitochondria
are uncoupled from microtubules (Rice and Gelfand, 2006).
This model is consistent with the ‘‘saltatory movement’’ model
proposed by Hajno´czky (Liu and Hajno´czky, 2009; Yi et al.,
2004), in which mitochondria move only when local [Ca2+] is
low, and stop when the local [Ca2+] is high. Notably, only Ca2+
mobilized via IP3Rs (or, in muscle, via the related ryanodine
receptors) could generate this result. We note, however, that
very few of the experiments supporting this model have been
conducted in mammalian neurons.
The tethering of mitochondria to ER via MAM is a dynamic
process, as organelles must disengage from the ER in order to
engage, and then travel on, microtubules. Any defect that alters
this equilibrium could conceivably result in a mismatch between
the number of mitochondria required in specific regions of a
neuron and the demand for mitochondrial cargo in those regions
(Schon and Area-Gomez, 2010). Given the dynamic nature of
MAM, and the role of IP3Rs in maintaining the proper equilibrium
between ER and mitochondrial [Ca2+], one can easily imagine
that neurodegenerative disorders in which calcium homeostasis
is disrupted could arise fromaltered ER-mitochondrial communi-
cation, or conversely, that alterations in calcium homeostasis
from some other cause could affect this communication indi-
rectly. Among our selected adult-onset neurodegenerative
diseases, two candidates are HD, in which both HTT and HAP1
interact with IP3R1 (Tang et al., 2003), and a form of SCA associ-
ated with loss of IP3R1 function (van de Leemput et al., 2007).
However, themost compelling case for a role for MAM in path-
ogenesis is familial AD due to mutations in presenilin-1 and -2,
which are components of the g-secretase complex that cleaves
the amyloid precursor protein (APP) to produce amyloid-b,
a constituent of the extracellular neuritic ‘‘plaques’’ that accumu-
late in the brains of AD patients (Schon and Area-Gomez, 2010).
Apart from the accumulation of hyperphosphorylated forms
of the microtubule-associated protein tau in intraneuronal
‘‘tangles’’ (the other prominent aspect of AD pathology), both
the familial and sporadic forms of the disease are characterized
by a number of other features that have received less attention.
These include altered lipid, cholesterol, and glucose metabolism
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(Supnet and Bezprozvanny, 2010), ER stress and the unfolded
protein response (Hoozemans et al., 2005), aberrant mitochon-
drial dynamics (e.g., fragmented and perinuclear mitochondria,
associated with, for example, altered levels [Wang et al.,
2009a] or posttranslational modifications [Cho et al., 2009] of
the mitochondrial fission protein dynamin-related protein-1
[DRP1]), and defects in energy metabolism (Ferreira et al.,
2010), but it remains to be determined to what degree these
phenomena are causally linked. It is in this context that a recent
report that presenilin-1 and –2 (and g-secretase activity itself) are
highly enriched in the MAM (Area-Gomez et al., 2009) is so inter-
esting, because the functions noted above that are perturbed in
AD are in fact the very functions associated with MAM. More-
over, even the generation of the plaques might be explained by
altered MAM function, as MAM-localized ACAT1, which is
required to convert intracellular cholesterol to cholesteryl esters
that are deposited in lipid droplets, is apparently a modulator of
APP processing and amyloid-b production (Puglielli et al., 2001),
for currently unknown reasons. Thus, pathogenic mutations in
the presenilins could alter ER-mitochondrial communication
(Zampese et al., 2011), leading to the features of the disease
(Schon and Area-Gomez, 2010).
One other neurodegenerative disease that may be associated
with MAM dysfunction is CMT, which can be caused by muta-
tions both in MFN2 (Chen and Chan, 2009) and in ganglioside-
induced differentiation-associated protein 1 (GDAP1) (Pedrola
et al., 2005), which interacts with MFN2 (Niemann et al., 2005).
MFN2, like mitofusin-1 (MFN1), is required for mitochondrial
fusion (Chen andChan, 2009). However, a portion ofMFN2 is en-
riched in the MAM, where it is required for the tethering of ER to
mitochondria (de Brito and Scorrano, 2008). We note that CMT
mutant MFN2 expressed in cultured dorsal root ganglion
neurons induced abnormal clustering of fragmented mitochon-
dria, as well as impaired axonal transport of mitochondria (Baloh
et al., 2007). Perhaps these abnormalities resulted from an
underlying defect in ER-mitochondrial communication.
The study of MAM is a nascent field that has just begun to be
recognized as a contributor to neurodegeneration, and likely will
expand beyond the diseases cited above. For example, there
may be a ‘‘MAM connection’’ in at least two other diseases in
which the relevant proteins—both involved in phospholipid
metabolism—appear to be enriched in the MAM. These are
SCA due to mutations in PPP2R2B, a regulatory subunit of
protein phosphatase 2A (Giorgi et al., 2010) that promotes mito-
chondrial fission (Dagda et al., 2008a), presumably via MAM-
localized FIS1 (Iwasawa et al., 2011), and PD due to mutations
in subunit b of the calcium-independent phospholipase A2
(iPLA2b; gene PLA2G6), which plays a key role in ER-mitochon-
drial crosstalk during ER stress-induced apoptosis (Lei et al.,
2008). It would thus be fascinating to see if future studies on
PPP2R2B and iPLA2b provide insight into a potential link
between MAM and neurodegeneration in SCA and PD, and
perhaps even beyond.
Neurodegenerative Disorders and Mitochondrial
Quality Control
Besides alterations in trafficking and in ER-mitochondrial
communication, mitochondria can also fail to reach their destina-tions due to dysregulation of quality control systems. The cell has
surveillance mechanisms to eliminate mutated, unfolded, and
otherwise unwanted proteins, via autophagic and ubiquitin-pro-
teasome systems located in the cytosol. In a similar manner,
unwanted mitochondria can be disposed of, and their contents
recycled, by mitophagy. Although there is currently no evidence
that mitochondria contain proteasomes, they do have mecha-
nisms to eliminate misfolded or unneeded polypeptides, via,
for example, the AAA (ATPase associated with diverse cellular
activities) protease paraplegin/SPG7 and the paraplegin-related
protease AFG3L2, and their regulators, the prohibitins PHB and
PHB2 (Osman et al., 2009). In addition, mitochondrial proteins,
especially those in the outer membrane, can be retrotranslo-
cated into the cytosol by, for example, mitochondrially targeted
valosin-containing protein (VCP/p97, also a AAA protease) (Xu
et al., 2011), for subsequent clearance by the proteasome. This
process constitutes, as it were, a mitochondrial version of
ER-associated degradation (Heo et al., 2010). Interestingly,
mutations in VCP were recently found to cause familial ALS
(Johnson et al., 2010).
Thus, mutations in mitochondrial quality control genes could
prevent the efficient elimination of damaged mitochondria and
the degradation of superfluous and potentially deleterious poly-
peptides, hence leading to neuronal dysfunction and perhaps
ultimately to cell death. In order for quality control to operate at
the level of the mitochondrion, cells must be able to distinguish
between ‘‘good’’ and ‘‘bad’’ organelles, and in fact, such dis-
crimination does occur. Mitochondria apparently are deemed
to be good if they have a high membrane potential (Dc), and
perhaps low levels of reactive oxygen species (ROS) as well,
both presumably indicative of a well-functioning respiratory
chain. Conversely, they are deemed bad if they have a low Dc
and elevated ROS, indicative of defective OxPhos; these are
the organelles that are eliminated via selective mitophagy
(Twig and Shirihai, 2011). Mitophagy of damaged organelles,
however, is a last resort, as cells initially try to prevent the accu-
mulation of bad mitochondria via maintenance of a dynamic
equilibrium between mitochondrial fission and fusion, which
‘‘homogenizes’’ organellar contents. This mixing of a few bad
mitochondria within a larger pool of good ones allows for
complementation of genes and gene products to take place after
mitochondria have exchanged contents (Gilkerson et al., 2008),
thereby blunting, or even eliminating, the deleterious effects of
misfolded proteins and randomly mutated mtDNAs (Twig and
Shirihai, 2011).
Thus, from a quality control standpoint, one might predict that
mutations in genes encoding proteins required for mitochondrial
dynamics, and especially organellar fission and fusion, would
result in compromised organellar ‘‘mixing,’’ leading to an excess
accumulation of bad mitochondria, perhaps causing disease,
and this is indeed the case. Gene products in this category
include four associated with fusion (although interestingly,
none with fission): MFN2 and GDAP1, both causing CMT, and
OA proteins OPA1 and OPA3, both causing OA. Even though
OPA1 and OPA3 (Huizing et al., 2010; Ryu et al., 2010) and
GDAP1 (Niemann et al., 2005) interact with mitofusins to regulate
the mitochondrial network, it is again worth noting that the
four genes are associated with two totally different clinicalNeuron 70, June 23, 2011 ª2011 Elsevier Inc. 1045
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(Bossy-Wetzel et al., 2008; Kim et al., 2010; Oliveira, 2010), as
the expression of mitochondrial fission-related proteins, such
as FIS1 and DRP1 (Costa et al., 2010), which happens to interact
with HTT (Song et al., 2011), are increased in striatum and frontal
cortex of patients, whereas that of fusion-related proteins, such
as MFN1, MFN2, and OPA1, are decreased (Shirendeb et al.,
2011), likely explaining the fragmented mitochondria and altered
mitochondrial dynamics seen in the disease (Pandey et al., 2010;
Shirendeb et al., 2011).
Among diseases in this category, PD stands out, as it is
becoming apparent that some genetic forms of the disease
may be in essence disorders of mitochondrial quality control.
Paradoxically, the history of PD, at least froma genetic/biochem-
ical perspective, pointed away from such a conclusion, as the
earliest observations regarding pathogenesis implied a defi-
ciency of complex I of the respiratory chain as the key culprit.
That conclusion was based on the findings that (1) 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), a complex I inhibitor
similar to rotenone, caused PD-like symptoms, (2) complex I
activity was reported to be reduced in PD postmortem tissues,
(3) mutations in complex I subunits, such as nDNA-encoded
NDUFV2, were associated with PD (Nishioka et al., 2010), and
(4) accumulations of large-scale deletions of mtDNA were found
specifically in the substantia nigra of sporadic PD patients
(Bender et al., 2006; Kraytsberg et al., 2006), the signature target
region of the brain in this disease (Dauer and Przedborski, 2003).
However, a notable challenge to this concept was the failure to
find clear evidence of mutations in mtDNA that cause PD (Simon
et al., 2010). Moreover, the identification in the last decade of at
least a dozen genetic loci associated with familial PD (Table 2)
has changed our perspective dramatically, as many of these
gene products are associated with mitochondria but have no
obvious or direct connection to OxPhos, and many of those
proteins appear to be involved in quality control.
Two of those PD-related proteins may be involved in quality
control in an indirect manner. Phospholipase A2, group VI
(PLA2G6) (Seleznev et al., 2006) is a mitochondrial lipase that
deacetylates cardiolipin and is involved in ER stress and
ER-mitochondrial crosstalk via ceramide (Lei et al., 2008).
GRB10-interacting GYF protein-2 (GIGYF2) enhances the acti-
vation of mitochondrially localized (Deng et al., 2000; Galli
et al., 2009) extracellular signal-regulated kinases ERK1 and
ERK2 (Deng et al., 2000; Higashi et al., 2010), both of which
are involved in mitophagy (Dagda et al., 2008b) and apoptosis
(Deng et al., 2000; Higashi et al., 2010).
Amuch stronger case for a role in mitochondrial quality control
can bemade for Parkin, a cytosolic E3 ubiquitin ligase. However,
in this role, Parkin does not act alone, as mounting evidence
implicates the necessary interaction with another PD-related
and mitochondrially localized protein, PINK1. PINK1 is a kinase
of unknown specificity that displays a possible dual location in
the organelle, i.e., it has been found in both the outer (Zhou
et al., 2008) and inner (Jin et al., 2010; Silvestri et al., 2005)
membranes. Mitochondrial PINK1 is present in two forms, long
and short, with the long form (PINK1-L, 64 kDa) cleaved to
the short form (PINK1-S,52 kDa) within the mitochondrial inner
membrane by presenilin-associated rhomboid-like protein1046 Neuron 70, June 23, 2011 ª2011 Elsevier Inc.(PARL), an intramembrane protease (Deas et al., 2011; Jin
et al., 2010).
As an aside, like PINK1, OPA1 also has long and short forms,
with OPA1-L cleaved, not by PARL, but by AFG3L2, to produce
OPA1-S (Duvezin-Caubet et al., 2007). The long forms of both
OPA1 and PINK1 are targeted to the inner membrane, where
cleavage occurs, essentially releasing the short forms of both
proteins to perform their functions. Whereas the function of
OPA1-S is clearly fusion of the mitochondrial outer membrane,
the precise role of PINK1-S remains to be determined. One
possibility is that PINK1 (Weihofen et al., 2009), which, like
MFN2 (Misko et al., 2010), interacts with the mitochondria-kine-
sin adaptors Miro and Milton, and with mitofilin (Weihofen et al.,
2009), another mitochondrial morphology-related protein (John
et al., 2005), assists in the offloading of mitochondria from
microtubules in order to allow them to fragment and become
autophagized (Gomes et al., 2011; Hailey et al., 2010).
However, the lion’s share of attention to PINK1 is devoted to
its relationship with Parkin in cooperating in a signaling pathway
(Clark et al., 2006) to maintain mitochondrial integrity, presum-
ably by eliminating bad mitochondria via mitophagy (Vives-
Bauza and Przedborski, 2011). As such, we deem the elucidation
of the biology of Parkin and PINK1 to be far more important in
illustrating the mitochondrial connection to neurodegenerative
disease than the few number of patients harboring mutations
in these proteins might warrant.
In the current view, upon loss of Dc in damaged mitochondria,
PINK1 residing in the outer membrane triggers, in some
unknown fashion, the recruitment of cytosolic Parkin to the mito-
chondria (Jin et al., 2010; Narendra et al., 2010b; Vives-Bauza
et al., 2010). Mitochondrial proteins located in the outer
membrane, such as the voltage-dependent anion channel 1
(VDAC1; also called porin) are then ubiquitinated in a Parkin-
dependent manner (Geisler et al., 2010). The ubiquitination of
outer membrane proteins recruits the autophagy molecule
microtubule-associated protein-1 light chain-3 (LC3) to build
the autophagosome around the damaged mitochondrion (Vi-
ves-Bauza and Przedborski, 2011), apparently mediated by the
adaptor proteins HDAC6 (Okatsu et al., 2010) and p62 (Geisler
et al., 2010; Narendra et al., 2010a; Okatsu et al., 2010). Upon
membrane depolarization, according to some studies, Parkin
also induces ubiquitination of mitofusins (Gegg et al., 2010; Zi-
viani et al., 2010), which are then degraded by the proteasome
via VCP (Tanaka et al., 2010), although others found that it is
DRP1 and not MNF1/2 or FIS1 that is degraded by the protea-
some in a Parkin-dependent manner (Wang et al., 2011). This
discrepancy needs to be resolved, as the exact fusion/fission
factors that are regulated by Parkin would indicate whether Par-
kin, either alone or in conjunction with PINK1, promotes frag-
mentation or elongation of mitochondria. Perhaps a-synuclein
may begin to provide some hints into this outstanding issue, as
overexpression of PD mutant and wild-type a-synuclein (which,
as noted above, mimics the gene multiplications found in some
PD patients) were reported to promote fragmentation of mito-
chondria (Kamp et al., 2010; Nakamura et al., 2011). Conversely,
downregulation of wild-type a-synuclein inC. elegans resulted in
elongatedmitochondria (Kamp et al., 2010). Although changes in
the fusion/fission balance have not yet been demonstrated in PD
Neuron
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a-synuclein would enhance, rather than hamper, mitochondrial
turnover, because fragmentation, and not elongation, of mito-
chondria into ‘‘bite-sized’’ pieces facilitates mitophagy (Twig
et al., 2008). Alternatively, rather than altering mitophagy,
perhaps a-synuclein influences quality control through its effect
on the fusion/fission balance by affecting the ability of good
mitochondria to complement bad ones.
The PD-related protein DJ-1 may also have a relationship to
quality control, as it has a number of proposed disparate
connections to mitochondria. In addition to possibly binding to
the NDUFA4 and ND1 subunits of complex I (Hayashi et al.,
2009a), DJ-1 has been reported to interact with both PINK1
and Parkin (Moore et al., 2005) and to modulate mitochondrial
fission/fusion in a ROS-dependent manner (Irrcher et al., 2010).
This latter effect is consistent with its proposed function as an
atypical peroxiredoxin-like peroxidase that scavenges mito-
chondrial H2O2 (Andres-Mateos et al., 2007). Moreover, DJ-1
seems to regulate the expression of the mitochondrial uncou-
pling (UCP) proteins, as its ablation in mice is associated with
reduced expression of UCP4 and UCP5 in brain (Guzman
et al., 2010). While these two UPCs are among the least well-
characterized members of this family, it is tantalizing to suggest
that changes in their expression in brain could alter mitochon-
drial Dc, which, if confirmed, would be an important clue as to
how DJ-1 participates in mitochondrial quality control. Indeed,
if as suggested from the PINK1/Parkin story, a loss of Dc is
a prerequisite for the disposal of bad mitochondria, the loss-
of-function mutations in DJ-1 that cause PD may impair mito-
chondrial quality control by distorting the relationships among
mitochondrial damage, Dc, and mitophagy. In this scenario,
DJ-1 would operate upstream of PINK1/Parkin within the mi-
tophagy pathway, an idea consistent with the demonstration
that silencing DJ-1 in human cell lines does not affect PINK1-
dependent recruitment of Parkin and ensuing mitophagy in
response to Dc collapse by protonophores (Vives-Bauza et al.,
2010). Clearly, further work is needed to determine how the func-
tion of PD-related proteins intersects with mitodynamics to
contribute to the pathogenesis of the disease.
The mitophagy model for pathogenesis in PD is appealing, as
it explains many of the features of the disease that have been
ascribed to mitochondrial dysfunction noted above. However,
there are aspects to this developing story that suggest caution
in accepting such a scenario uncritically. First, deletion of
PINK1, Parkin, or DJ-1 in mice, either alone or in combination,
had little perceptible effect on neuronal function (Kitada et al.,
2009), calling the role of mitophagy in the pathogenesis of the
disease into question. Equally important is the relative artificiality
of some of the experimental manipulations upon which the role
of these proteins has been based. Because both PINK1 and
Parkin are present at low levels, most conclusions are derived
from overexpression experiments. Furthermore, the lack of
good antibodies has required the use of epitope tags to detect
these proteins. Finally, the complete disruption of mitochondrial
Dc using ionophores such as carbonyl cyanide m-chlorophenyl
hydrazone (CCCP) does not mimic the much lower degree of
disruption of Dc that likely occurs in patients; even cells that
lack mtDNA and OxPhos function entirely can maintain about50% of the wild-type Dc. Thus, while the concept of mitochon-
drial quality control as a pathogenic principle in PD remains
appealing, some aspects of the current model may require
modification.
We would be remiss if we failed to mention that quality control
has more than a janitorial function, as it is also required to
maintain normal cellular and organellar processes. For example,
themajormitochondrial matrix AAAprotease, besides degrading
misfolded proteins (T. Langer, personal communication), regu-
lates mitochondrial ribosome biogenesis by processing the
mitochondrial ribosomal protein MRPL32 for proper incorpora-
tion into, and functioning of, mitochondrial ribosomes. Consis-
tent with this function, the loss of either SPG7 or AFG3L2 (Nolden
et al., 2005), the two subunits that compose the matrix AAA
protease, compromises mitochondrial translation, resulting in
bioenergetic impairment (Atorino et al., 2003; Nolden et al.,
2005). Together with the fact that mutations in SPG7 cause
HSP (Casari et al., 1998) and mutations in AFG3L2 cause SCA
(Di Bella et al., 2010), the aforementioned findings suggest that
defects in mitochondrial ribosomal biogenesis via defects in
quality control can provoke neurodegeneration.
Concluding Remarks
For years, defects in OxPhos and oxidative stress have been two
of the most popular hypotheses put forward to explain patho-
genesis of almost all neurodegenerative disorders. It is clear
that ‘‘classical’’ mitochondrial diseases, many of which are
myopathies and encephalopathies in children and young adults,
are unquestionably provoked by bioenergetic defects. However,
when we look at the data critically, the role of impaired bioener-
getics as the primary cause of late-onset neurodegenerative
diseases is far less compelling, even in the case of disorders
when there are known mutations in OxPhos genes, such as in
LHON. If so, how can we reconcile a role for mitochondria in
these disorders, given the large literature implicating energy
metabolism? Perhaps the recent shift in emphasis regarding
the role of mitochondria in neurodegenerative disorders reflects
a better appreciation of the relationship between cause and
effect in these diseases, namely, that impaired OxPhos is not
the cause of neurodegeneration, but is one result of other under-
lying mitochondrial problems. Furthermore, we recognize that
while changes in mitochondrial function do not necessarily
have to affect bioenergetic output, the fact remains that if, for
example, mitodynamics are perturbed, the absolute production
and local delivery of ATP will be reduced, and that at some point
in the disease process bioenergetic failure will occur, probably
delivering the coup de graˆce.
We have entered a new era of mitochondrial biology, one in
which the focus is no longer solely on bioenergetics per se but
on mitochondria as an integrated subcellular system (Figure 1).
Under this rubric, a central theme that has emerged is one of
altered mitochondrial dynamics. While important advances
have been made in this area in a relatively short period of time,
some key outstanding questions still remain to be addressed.
For example, if diseases such as AD, ALS, and PD are due to
errors in mitochondrial quality control overseen by a suite of
ubiquitous housekeeping proteins, why do these diseases
display a predilection for specific subpopulations of neurons?Neuron 70, June 23, 2011 ª2011 Elsevier Inc. 1047
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specific neurons may be more vulnerable to the pathological
process than others; clearly, such a differential neuronal suscep-
tibility will only reveal itself if the defect in question is mild, as
would be expected for an adult-onset neurodegenerative
disorder.
Based on this premise, let us use PD to illustrate a putative
pathogenic scenario, by comparing two subpopulations of dopa-
minergic neurons from the ventral midbrain that are affected
differentially in the disease, namely those in the substantia nigra
(severely affected) and those in the ventral tegmental area (mildly
effected) (Dauer and Przedborski, 2003). One compelling differ-
ence between these two groups of neurons is that recruitment
of L-type calcium channels during normal autonomous pace-
making is associated with a high ROS signal in dopaminergic
neurons of the substantia nigra, but not those of the ventral
tegmental area (Guzman et al., 2010). Thus, one could speculate
that the former region accumulates a much higher burden of
ROS-related mtDNA mutations than the latter, a view that is, in
fact, supported by the observation that dopaminergic neurons
in the substantia nigra of both aged normal subjects (Kraytsberg
et al., 2006) and PD patients (Bender et al., 2006) contain more
mtDNA deletions than do those from controls. Thus, if the ‘‘mito-
chondrial quality control’’ hypothesis for the pathogenesis of
neurodegenerative disorders is correct, one would predict that
unless properly eliminated bymitophagy, the number of function-
ally deficient mitochondria would slowly increase over time to
amuch greater extent in those neurons generatingmoremutated
mtDNAs (i.e., substantia nigra), eventually causing functional
perturbations and neuronal death. Extending this idea further, if
mitophagy is important in other adult-onset neurodegenerative
disorders, many of which are sporadic, one might also expect
that other risk factors, both genetic and environmental, would
affect mitophagy and thereby induce the pathology. These risk
factors, if they exist, remain to be uncovered.
We have divided our discussion of mitodynamics into three
areas—trafficking, organelle interconnectivity, and quality
control—mainly for convenience, but we consider all three to
be intertwined aspects of a larger whole. In keeping with this
view, we note that the analysis of pathogenic mechanisms in
essentially all of our selected disorders encompassed more
than one of these areas, underscoring the integrative nature of
mitodynamics, in which a problem in one area can readily have
consequences in another one, including bioenergetics.
Finally, while we have focused in this review almost exclusively
on mitochondria, we do not want to leave the impression that
mitochondrial defects are the sine qua non of neurodegenerative
disease. Far from it: of the 106 genes that were mentioned at
the outset, we have discussed fewer than half; the remainder
have no obvious connection to mitochondria, and yet they cause
neurodegeneration. Moreover, we wish to reiterate that we have
focused on familial forms of common neurodegenerative disease
as one way to provide a window onto pathogenesis of their
sporadic counterparts. This assumption, of course, remains to
be validated.
Can any of the above discussion inform ideas about thera-
peutic strategies for neurodegenerative disorders? Based on
the insights into mitochondrial behavior in these disorders, one1048 Neuron 70, June 23, 2011 ª2011 Elsevier Inc.can begin to envision pharmacological approaches to treatment.
For example, regarding mutations in mtDNA, one strategy could
be to eliminatemutatedmtDNAswhile leavingwild-typemtDNAs
intact, in order to reduce the load of mutated mtDNAs below
a critical threshold. One such way to shift heteroplasmy is to
force cells harboring high levels of partially deleted mtDNAs to
eliminate bad mitochondria that contain predominantly mutated
mtDNAs while, at the same time, sparing good ones that contain
predominantly normal mtDNAs by growing them in ketogenic
media that selects for well-functioning mitochondria (Santra
et al., 2004). A shifting approach might work particularly well in
diseases like PD, in which substantia nigra is known to contain
relatively high levels of mtDNA deletions (Bender et al., 2006).
The role of the PD-related proteins PINK1 and Parkin in mitoph-
agy points to another way to eliminate bad mitochondria selec-
tively, namely, by upregulating the autophagic pathway. An
obvious proautophagic candidate drug would be rapamycin,
which has already been shown to protect against neuronal death
in mouse models of PD (Malagelada et al., 2010). For mutations
in other genes associated withmitochondrial function, and espe-
cially those that impair function only partially, a third promising
approach might be to increase energy production in patients
by upregulating PGC-1a expression using compounds such as
bezafibrate, a PPAR panagonist (Santra et al., 2004), or 5-amino-
imidazole-4-carboxamide ribonucleoside (AICAR), which acts as
an AMP agonist by mimicking AMP (Viscomi et al., 2011). Finally,
it may be possible to alter mitodynamics directly by, for example,
shifting the relationship between fission and fusion pharmaco-
logically, using the quinazolinone mitochondrial division inhibitor
1 (mdivi1), which enhances mitochondrial fusion in yeast by
inhibiting the mitochondrial dynamin Dnm1 that is required for
organelle fission (Cassidy-Stone et al., 2008).
We may view the role of mitochondria in the pathogenesis of
neurodegenerative disorders, and the ways in which we have
begun to think about therpaeutics, as multifaceted, and going
well beyond the ‘‘mere’’ synthesis and distribution of ATP
throughout cells. Mitochondria encompass numerous functions,
including many important ones that have not even been dis-
cussed here (e.g., amino acid metabolism, steroid metabolism,
apoptosis, xenobiotic detoxification, and immunological
defense), all of which could play a role in neurodegenerative
disorders. To the cliche´ that mitochondria are the powerhouses
of the cell, let us add one more: what has been uncovered in the
last 10 years regarding the role of mitochondria in neurodegen-
erative disorders is merely the tip of the iceberg. Far more
exciting findings lay ahead.ACKNOWLEDGMENTS
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